slides · global inventory
Resolution
Beat collection for the active corpus filters, with each row opening the slide detail view.
Matching slides 42,534
Current window 32,191-32,220
Pages 1,418
Rows per page 30
Beat
32,191-32,220 of 42,534
64
Includes company logo, tagline, mission statement, date, and ticker symbol.Immix Biopharma | Investor Presentation Deck | 64 slides · Immix Biopharma
Deck Investor relations Beat · Impact & Next Steps1 hit
11
jetBlue | Results Presentation Deck | 17 slidesjetBlue | Results Presentation Deck | 17 slides · JetBlue
Conference presentation Investor relations Beat · ActionLoop · Cost Of Inaction1 hit
12
jetBlue | Results Presentation Deck | 17 slidesjetBlue | Results Presentation Deck | 17 slides · JetBlue
Conference presentation Investor relations Beat · Action1 hit
13
Includes reconciliation of CASM to CASM Ex-Fuel.jetBlue | Results Presentation Deck | 17 slides · JetBlue
Conference presentation Investor relations Beat · Action1 hit
14
The slide provides a detailed breakdown of adjustments for Spirit costs, union contract costs, and fleet transition costs.jetBlue | Results Presentation Deck | 17 slides · JetBlue
Conference presentation Investor relations Beat · Action1 hit
15
This is a continuation slide for a non-GAAP financial reconciliation.jetBlue | Results Presentation Deck | 17 slides · JetBlue
Conference presentation Investor relations Beat · Action1 hit
16
jetBlue | Results Presentation Deck | 17 slidesjetBlue | Results Presentation Deck | 17 slides · JetBlue
Conference presentation Investor relations Beat · Action1 hit
17
jetBlue | Results Presentation Deck | 17 slidesjetBlue | Results Presentation Deck | 17 slides · JetBlue
Conference presentation Investor relations Beat · Action1 hit
26
KeyCorp | Results Presentation Deck | 30 slidesKeyCorp | Results Presentation Deck | 30 slides · KeyCorp
Conference presentation Investor relations Beat · Resolution1 hit
27
Data presented in millions of dollars.KeyCorp | Results Presentation Deck | 30 slides · KeyCorp
Conference presentation Investor relations Beat · Resolution1 hit
28
Includes footnotes regarding intangible assets and purchased credit card receivables.KeyCorp | Results Presentation Deck | 30 slides · KeyCorp
Conference presentation Investor relations Beat · Resolution1 hit
29
The slide presents three distinct financial tables grouped by metric type.KeyCorp | Results Presentation Deck | 30 slides · KeyCorp
Conference presentation Investor relations Beat · Resolution1 hit
30
The table breaks down pre-tax amounts, after-tax net income, and EPS impact for items like efficiency expenses, pension settlements, and FDIC assessments.KeyCorp | Results Presentation Deck | 30 slides · KeyCorp
Conference presentation Investor relations Beat · Resolution1 hit
18
Lionsgate | SPAC Presentation Deck | 30 slidesLionsgate | SPAC Presentation Deck | 30 slides · Lionsgate
Conference presentation Investment bank Beat · The AskLoop · Why Now1 hit
19
The slide uses a flow-based diagram to show asset contributions and equity stakes.Lionsgate | SPAC Presentation Deck | 30 slides · Lionsgate
Conference presentation Investment bank Beat · The AskLoop · Why Now1 hit
23
The chart illustrates a bridge from 21,055 M€ in 2022 to 22,802 M€ in 2023.LVMH | Results Presentation Deck | 31 slides · LVMH
Conference presentation Investor relations Beat · ActionLoop · Before After1 hit
24
The table shows a breakdown of financial costs and adjustments, with a total net financial result change of -47 million euros.LVMH | Results Presentation Deck | 31 slides · LVMH
Conference presentation Investor relations Beat · ActionLoop · Before After1 hit
25
The slide uses a stacked bar chart to represent the balance sheet structure.LVMH | Results Presentation Deck | 31 slides · LVMH
Conference presentation Investor relations Beat · Action1 hit
26
The table breaks down cash flow from operations, net cash from operating activities, and operating free cash flow.LVMH | Results Presentation Deck | 31 slides · LVMH
Conference presentation Investor relations Beat · Action1 hit
27
The chart combines a bar chart for debt (in millions of euros) and a line chart for the gearing percentage.LVMH | Results Presentation Deck | 31 slides · LVMH
Conference presentation Investor relations Beat · Action1 hit
28
The 2023 dividend is subject to approval at the Annual General Meeting.LVMH | Results Presentation Deck | 31 slides · LVMH
Conference presentation Investor relations Beat · Action1 hit
03
The slide outlines the status of THIO-101, 102, and 103, highlighting FDA designations and clinical trial progress.MAIA Biotechnology | Investor Presentation Deck | 31 slides · MAIA Biotechnology
Pitch deck Investor relations Beat · The Ask1 hit
08
Uses a before-after-bridge style logic to frame the solution.Matinas BioPharma | Investor Presentation Deck | 29 slides · Matinas BioPharma
Pitch deck Investor relations Beat · Problem (Identify pain)Loop · Cost Of Inaction1 hit
09
The slide uses a process flow diagram to map clinical outcomes to specific trial metrics.Matinas BioPharma | Investor Presentation Deck | 29 slides · Matinas BioPharma
Pitch deck Investor relations Beat · Problem (Identify pain)Loop · Cost Of Inaction1 hit
10
This is a citation slide showcasing scientific validation of the company's technology.Matinas BioPharma | Investor Presentation Deck | 29 slides · Matinas BioPharma
Pitch deck Investor relations Beat · Problem (Identify pain)Loop · Cost Of Inaction1 hit
11
The slide uses a human silhouette as a central diagram to map specific fungal pathogens and resulting conditions to anatomical locations.Matinas BioPharma | Investor Presentation Deck | 29 slides · Matinas BioPharma
Pitch deck Investor relations Beat · Problem (Identify pain)Loop · Cost Of Inaction1 hit
12
Focuses on clinical success in a compassionate use setting.Matinas BioPharma | Investor Presentation Deck | 29 slides · Matinas BioPharma
Pitch deck Investor relations Beat · Problem (Identify pain)Loop · Cost Of Inaction1 hit
13
The slide uses a timeline-based case study format to demonstrate clinical efficacy and safety.Matinas BioPharma | Investor Presentation Deck | 29 slides · Matinas BioPharma
Pitch deck Investor relations Beat · Problem (Identify pain)Loop · Cost Of Inaction1 hit
14
The slide highlights both the clinical urgency (toxicity, resistance) and the commercial potential (orphan disease status).Matinas BioPharma | Investor Presentation Deck | 29 slides · Matinas BioPharma
Pitch deck Investor relations Beat · Problem (Identify pain)Loop · Cost Of Inaction1 hit
15
Focuses on clinical trial strategy and regulatory milestones.Matinas BioPharma | Investor Presentation Deck | 29 slides · Matinas BioPharma
Pitch deck Investor relations Beat · Solution (Provide relief)Loop · Quick Win Big Bet1 hit